NeuroDerm (NDRM) Posts Stronger Q1 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to NeuroDerm (NDRM) Posts Stronger Q1 Profit
May 27, 2015 7:00 AM EDT
REHOVOT, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2015 and provided a corporate update.
"We look forward to the start of our next clinical trial, a head-to-head pilot pharmacokinetic study comparing ND0612H, our subcutaneously delivered high dose product candidate for advanced Parkinson's disease, with Duodopa®, an intraduodenally-delivered product requiring surgery. Pending the study's outcome, we plan to conduct a definitive pharmacokinetic similarity study of... More
May 27, 2015 7:00 AM EDT
REHOVOT, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2015 and provided a corporate update.
"We look forward to the start of our next clinical trial, a head-to-head pilot pharmacokinetic study comparing ND0612H, our subcutaneously delivered high dose product candidate for advanced Parkinson's disease, with Duodopa®, an intraduodenally-delivered product requiring surgery. Pending the study's outcome, we plan to conduct a definitive pharmacokinetic similarity study of... More
